Rethinking the Approach- Management of Elevated LDL-C in Patients with ASCVD
This presentation reviews the large burden of illness of ASCVD in the US population. It covers the numerous ways that high-risk ASCVD patients present and discuss important risk-enhancing factors and co-morbidities. Lastly, data is presented on the pivotal clinical trial results and baseline study population demographics supporting the FDA approval of a lipid lowering therapy, with a novel mechanism of action. Data includes LDL-C absolute and time-averaged reduction over trial duration, safety profile and appropriate patient population for considering appropriate use.
Identify and qualify the most important risk factor(s) for ASCVD on a population level
- Accurately identify prevalence/burden of ASCVD in the US, as well as heterogeneous group of diseases which encompasses ASCVD
- Have ability to understand the LDL-C role in ASCVD through both exposure duration and magnitude of plaque burden among patients
- Awareness of multi-specialty guideline directed optimal LDL-C threshold levels
- Possess awareness of additional therapeutic option for select ASCVD patients who require additional lowering of LDL-C beyond baseline therapy
Speaker: Jason LeCocq MD, MBA, Senior Medical Director, Atherosclerosis, US CLINICAL DEVELOPMENT & MEDICAL AFFAIRS, Cardiovascular & Metabolism, Novartis Pharmaceuticals Corporation
Virtual Platform: GoToWebinar
Target Audience: Health Care Practitioners and Clinicians who manage patients with Atherosclerotic Cardiovascular Disease
Date: Thursday November 17, 2022
Time: 12:00 – 1:00 pm ET
Important: This a 2 step registration process -
After registering on this site, you will receive a confirmation email with instructions to register with GoToWebinar to receive your logon instructions and calendar reminder. If you don't receive confirmation email...check your spam/junk folder.
This webinar is sponsored by:
US Medical Affairs